Latest News Archive

Please select Category, Year, and then Month to display items
Categories
UFS News Media Release Research
Years
2019 2020 2021 2022 2023 2024 2025
Months
January February March April July May June August September October November December
Previous Archive
07 July 2023 | Story André Damons | Photo Supplied
Dr Osayande Evbuomwan
Dr Osayande Evbuomwan, Senior Lecturer and Medical Specialist in the Department of Nuclear Medicine at the University of the Free State (UFS), with his certificate after winning the Society of Nuclear Medicine and Molecular Imaging (SNMMI) International Best Abstract Award for South Africa.

A research paper by a Senior Lecturer and Medical Specialist in the Department of Nuclear Medicine at the University of the Free State (UFS) has won the Society of Nuclear Medicine and Molecular Imaging (SNMMI) International Best Abstract Award for South Africa.

The abstract, by Dr Osayande Evbuomwan, was about evaluating the efficacy of a new nuclear medicine radiopharmaceutical in the identification of active disease in patients with rheumatoid arthritis. It was selected for this award by a special committee at the recently concluded SNMMI 2023 Annual Meeting, which took place between 24 and 27 June in Chicago, USA.

Dr Evbuomwan received the award at the Annual Meeting on 26 June.

“It is a good feeling, and I am proud of the UFS Department of Nuclear Medicine for pulling this off. It is another example that hard work pays,” he says.

Comparing this radiopharmaceutical to ultrasound

Dr Evbuomwan says the research that generated the award-winning abstract was aimed at finding out if the new nuclear medicine radiopharmaceutical for the identification of active disease in patients with rheumatoid arthritis can also offer prognostic information. The study concluded that this particular radiopharmaceutical (Tc – 99m glucosamine) is highly sensitive in identifying synovitis (inflammation of the membrane that protects joints), and is capable of offering prognostic information in patients with rheumatoid arthritis.

This is the first prospective study to assess the prognostic value of this radiopharmaceutical in patients with rheumatoid arthritis, Dr Evbuomwan says. He is currently working on comparisons of this radiopharmaceutical to ultrasound and clinical evaluation in the identification of active disease in patients with rheumatoid arthritis. He says there is also ongoing collaboration with the Rheumatology Division of the Internal Medicine Department, which has played a huge role in making this project fruitful.

“This award is an opportunity to put the department and university on the map, with world stage recognition. We believe that as the Nuclear Medicine Department continues to grow in human resources and equipment, the research output will also increase.”

Dr Gerrit Engelbrecht, Clinical Head of the Department of Nuclear Medicine at the UFS, says the whole department is very proud of Dr Evbuomwan’s accomplishments. “What makes his award even more remarkable is that he outperformed candidates from much larger, highly funded institutions,” he says.

This department announced last year the successful treatment outcome of a patient with metastatic castrate-resistant prostate cancer (MCRPC) – an advanced stage of prostate cancer – by using Lutetium 177 PSMA (Lu-177 PSMA) therapy. This was initially a case of advanced stage prostate cancer, which had failed first-line chemotherapy, leaving little or no other treatment options.

News Archive

Update on the Review of the Language Policy of the UFS
2015-11-26

On 5 June 2015, the Council of the University of the Free State (UFS) mandated Management to conduct a review of the Language Policy. The University Management Committee (UMC) then established a Language Committee to undertake a comprehensive review of the existing parallel-medium policy and to make recommendations on the way forward with respect to the university's Language Policy.

The Language Committee has now completed its work and the review report and its recommendations were presented to the UMC, the Executive Committee of Senate (ECS), as well as the full Senate. Each of these bodies debated the report and its recommendations and the views of these various structures will be presented to Council on 4 December 2015.

Council will study the report of the Language Committee and deliberate on the recommendations and views of these different university bodies ahead of, and at its December 2015 meeting. At that meeting, Council will then decide whether or not to accept the findings and recommendations of the Language Committee.

Should Council decide that - having reviewed the committee report - a new Language Policy must be developed, it would then mandate that such a policy should be designed and presented to itself as the highest decision-making authority of a university. In that case, the new Language Policy would have to be presented again to the UMC and Senate for voting purposes and that vote would be formally presented to Council at one of its meetings in 2016. The Institutional Forum, a statutory body that represents all university stakeholders, would also at that point advise Council, per its mandate, on a new Language Policy.

In the event that a new Language Policy is accepted by Council in 2016, the earliest possible date for implementation would be January 2017.

Economic and Management Sciences

Education

Health Sciences

The Humanities

Law

Natural and Agricultural Sciences

Theology and Religion

Open Distance Learning

Business School

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept